Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | TRPV3 | Q8NET8 | 5/20 | 0.42 |
| ▸ | KIF11 | P52732 | 3/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.38 |
| ▸ | HEXA | P06865 | 1/20 | 0.38 |
| ▸ | HEXB | P07686 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12538714 | 0.85 | TRPV3 (0.50) | LMNATHRBTRPV3KIF11S1PR1 | |
| SCHEMBL25979339 | 0.84 | NPC1 (0.49) | LMNAKIF11 | |
| SCHEMBL5219754 | 0.83 | LMNA (0.43) | LMNATHRBTRPV3KIF11S1PR1 | |
| SCHEMBL5249070 | 0.83 | TRPV3 (0.43) | LMNATHRBTRPV3KIF11ADORA3 | |
| SCHEMBL27942884 | 0.83 | DPP4 (0.46) | LMNATHRBTRPV3KIF11S1PR1 | |
| SCHEMBL14983666 | 0.81 | IDO1 (0.47) | — | |
| SCHEMBL14983674 | 0.80 | NPC1 (0.42) | LMNAKCNH2 | |
| SCHEMBL6017152 | 0.80 | TRPV3 (0.46) | LMNATHRBTRPV3KCNH2 | |
| SCHEMBL1549695 | 0.80 | KCNH2 (0.41) | LMNATHRBTRPV3KIF11S1PR1 | |
| SCHEMBL5202727 | 0.80 | TRPV3 (0.46) | LMNATHRBTRPV3KIF11S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1036066-B1 | SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES | MID AMERICA COMMERCIALIZATION (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20040033896-A1 | E.g., 5-ethyl-4-((3 -(trifluoromethoxy)phenyl)methyl)-2-(3-(trifluoromethyl)-1H pyrazol-1-yl)pyrimidine and 5-methyl-2-(4-(trifluoromethyl)phenyl)-4-((3-(trifluoromethyl) phenyl)methyl)pyrimidine | KOETHER GERARD (US) | 2004-02-19 | — | — | US | disclosed |
| US-6525001-B1 | 5-methyl-2-(4-(trifluoromethyl)phenyl)-4-((3 -(trifluoromethyl)phenyl)methyl)pyrimidine | MID-AMERICAN COMMERCIALIZATION CORPORATION | 2003-02-25 | — | — | US | disclosed |
| EP-1036066-A1 | SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999028301-A1 | SUBSTITUTED PYRIMIDINE AND PYRIDINE HERBICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033896-A1 | E.g., 5-ethyl-4-((3 -(trifluoromethoxy)phenyl)methyl)-2-(3-(trifluoromethyl)-1H pyrazol-1-yl)pyrimidine and 5-methyl-2-(4-(trifluoromethyl)phenyl)-4-((3-(trifluoromethyl) phenyl)methyl)pyrimidine | PYM1, Q6ZSR9, MRM1 | LMNA 3056/4885THRB 3346/4885TRPV3 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.